On Jan. 18, 2021, Humanigen announced a peer-reviewed publication in the Journal of Medical Economics citing the clinical and associated health economic benefits of lenzilumab.

The publication demonstrated, in all cases, lenzilumab plus SOC improved all specified clinical outcomes compared with SOC alone.